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Background. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are eﬀective in patients with
nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal
interstitial lung disease (ILD). The selection of chemotherapy based on the EGFR mutation status is recommended, however,
the frequency of EGFR mutation in patients with ILD and the eﬃcacy and safety of EGFR-TKI in patients with ILD and EGFR
mutation are unknown. Methods. We retrospectively reviewed the association of the EGFR mutation status of nonsmall cell lung
cancer and pulmonary diseases. Based on high-resolution computed tomography (HRCT) performed at diagnosis of lung cancer,
patients were categorized into three groups: normal, emphysema, and ﬁbrosis. Results. Of 198 patients with nonsmall cell lung
cancer, we identiﬁed 52 (26.3%) patients with an EGFR mutation. EGFR mutations were identiﬁed in 43 (35.2%) of 122 patients
with normal lungs, 8 (13.6%) of 59 with emphysema, and 1 (5.9%) of 17 with pulmonary ﬁbrosis. Of the 52 patients with EGFR
mutation, 43 patients received geﬁtinib. One patient with an EGFR mutation and ﬁbrosis developed fatal ILD. There was not a
signiﬁcant diﬀerence in median overall survival from geﬁtinib treatment between never-smokers and smokers (797 days versus
not reached; P = 0.96). Conclusions. Patients with sensitive EGFR mutation and normal lungs may beneﬁt from an EGFR-TKI
treatment even if they have smoking history.
1.Introduction
Geﬁtinib is a reversible epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI) used for the treatment
of nonsmall cell lung cancer patients [1]. Although demo-
graphic and clinical factors such as East-Asian race, female
gender, nonsmoking status, and adenocarcinoma were
shown to be predictive of the eﬃcacy of geﬁtinib, two pivotal
studies showed that the presence of somatic mutations in the
kinase domain of epidermal growth factor receptor (EGFR)
strongly correlates with increased responsiveness to EGFR-
TKIs in patients with nonsmall cell lung cancer [2, 3]. It
was later found that the subgroups of patients with nonsmall
cell lung cancer who had sensitivity to geﬁtinib had a high
incidence of EGFR mutations [4, 5]. Selecting patients on
the basis of EGFR mutations, rather than clinical factors,
would likely result in a population with a greater sensitivity
to geﬁtinib. First-line geﬁtinib for patients with advanced
nonsmall cell lung cancer who are selected on the basis of
EGFR mutations improves progression-free survival, with
acceptable toxicity, compared with standard chemotherapy,
although it failed to prolong overall survival [6, 7].
However, EGFR-TKI increases the risk of developing life-
threatening interstitial lung diseases (ILDs). The estimated
incidence of ILD is low in many countries (e.g., 0.3% in
the United States) [8] but is relatively high (4 to 6%) in
Japan [9, 10]. An older age, poor World Health Organization
performance status, reduced normal lung area on computed2 Pulmonary Medicine
tomography scans, preexisting chronic ILD, and concurrent
cardiac diseases are known as risk factors for ILD in geﬁtinib
treatment [10]. Although an assessment of pulmonary
comorbidities, especially ILDs, is important to decrease the
incidence of ILD induced by chemotherapy, the frequency of
EGFR mutation in patients with pulmonary ﬁbrosis and the
clinical feature of these patients are not clear.
We reviewed 198 patients who were examined for EGFR
mutation status and assessed the association of EGFR
mutations with the underlying pulmonary diseases on chest
high-resolution computed tomography (HRCT).
2. Methods
The medical records of a series of consecutive patients
with histologically- or cytologically-proven lung cancer,
who were tested for EGFR mutation status in the Divi-
sion of Diagnostic Pathology, NTT Medical Center Tokyo
betweenApril2008andNovember2010,wereretrospectively
reviewed. The status of EGFR mutation was examined in
a clinical practice, not investigational setting, to decide the
indication of EGFR-TKI treatment. Although most patients
with severe pulmonary ﬁbrosis or squamous cell carcinoma
were excluded from the EGFR mutation test in this period,
gender,smokingstatus,andtheexistenceofemphysemawere
not considered as the exclusion criteria of the test. Patients
withemphysemaandﬁbrosisonchestHRCTatthediagnosis
of lung cancer were prospectively identiﬁed, and the data
before lung cancer treatmentwas recorded to assess their risk
of ILD. Only patients who had a chest HRCT scan, which
was performed at diagnosis of lung cancer and was available
for review, were included in the study. The study protocol
was reviewed and approved by the Ethics Committee of NTT
Medical Center Tokyo.
Patients were categorized into three groups; those with
normal lungs (except for the tumor), emphysematous lungs,
orﬁbroticlungs,basedonchestCTﬁndingsasdescribedpre-
viously[11, 12]. Patients who met the following criteria were
categorized as having emphysema: the presence of emphy-
sema on CT, deﬁned as well-demarcated areas of decreased
attenuation in comparison with contiguous normal lung,
and marginated by a very thin (<1mm) wall or no wall,
and/or multiple bullae (>1cm) with upper zone predomi-
nance. Patients who met the following criteria were catego-
rized as having ﬁbrosis: the presence of diﬀuse parenchymal
lung disease with signiﬁcant pulmonary ﬁbrosis on CT,
deﬁned as reticular opacities with peripheral and basal pre-
dominance, honeycombing, architectural distortion, and/or
traction bronchiectasis or bronchiolectasis; focal ground-
glass opacities and/or areas of alveolar condensation may be
associated, but should not be prominent. Patients who met
neither criterion emphysema nor ﬁbrosis were categorized
as normal. The electronic medical records were reviewed
to obtain clinical and demographic data, including gender,
age, smoking history, histology results, clinical stage of lung
cancer, treatment, treatment-related toxicities, and survival.
2.1. EGFR Mutation Analysis. The presence of EGFR muta-
tions was determined by the peptide nucleic acid-locked
nucleicacidPCRclampmethodasdescribedpreviously[13].
The investigated EGFR-TKI sensitive mutations included
G719C, G719S, G719A, L858R, L861Q, and exon 19 dele-
tions, as well as a geﬁtinib-resistant mutation, T790M.
2.2. Statistical Analysis. Diﬀerences among the categorized
groups were compared using either the two-sided chi-square
test or Fisher’s exact test. The survival was estimated by the
Kaplan-Meier method, and diﬀerences in survival between
the subgroups were analyzed by the log rank test. Data were
analyzed using the StatView version 5.0J software package
(Statistical Analysis Systems, Cary, NC, USA).
3. Results
3.1. Subtypes of EGFR Mutations. We examined the EGFR
mutation status in 202 patients between April 2008 and
November 2010. We excluded 4 patients from this study
for the following reasons: one had small cell lung cancer,
two had gastric cancer, and one had parotid cancer. Of the
198 patients with nonsmall cell lung cancer, 52 patients
(26.3%) had EGFR-TKI-sensitive EGFR mutations, and
one patient had an EGFR-TKI-resistant mutation (T790M)
with an EGFR-TKI-sensitive mutation (Exon 19 deletion).
The patient population in this analysis (Table 1) was a little
young, including more female, less never-smoker, and less
squamous cell carcinoma of the lung in comparison with the
lung cancer cohort that we previously published [12].
3.2. The Variables Associated with the EGFR Mutation Status.
We investigated the association of several variables with
the EGFR mutations (Table 2). A two-sided chi-square test
showedthatgender(female),smokingstatus(neversmoker),
histology(adenocarcinoma),andchestCTﬁndings(normal)
were signiﬁcantly associated with the presence of an EGFR
mutation. Of 122 patients with normal lungs, 69 patients
had no history of smoking and 53 patients had a history
of smoking. The frequency of EGFR mutations (n,% )i n
patients with normal lungs did not diﬀer between smokers
(17, 32.1%) and never-smokers (26, 37.7%) (P = 0.5698).
3.3. Prognosis of Patients with EGFR Mutations Treated with
Geﬁtinib. All patients with an EGFR mutation were treated
in the Division of Respirology and Chest Surgery, NTT Med-
ical Center Tokyo. Of the 52 patients with EGFR mutation,
43 patients received geﬁtinib. The clinical characteristics of
the patients with an EGFR mutation treated with geﬁtinib
are shown in Table 3. The median survival after geﬁtinib
treatment was 797 days. We identiﬁed ILD in two patients
during geﬁtinib treatment; one had no ILD before geﬁtinib
treatment and one had pulmonary ﬁbrosis. The patient
with pulmonary ﬁbrosis developed acute exacerbation of
preexisting ILD on day 7 of geﬁtinib treatment and died on
day 14 because of ILD. The survival curves of the 42 patients,
excluding the patient with pulmonary ﬁbrosis, according
to smoking status and chest CT results, are shown in
Figures 1(a) and 1(b),r e s p e c t i v e l y .N od i ﬀerences in survival
were observed between smokers (n = 18, MST not reached)
and never-smokers (n = 24, MST 797 days) or betweenPulmonary Medicine 3
Table 1: Patient characteristics NSCLC: nonsmall cell lung cancer:
LCNEC; large cell neuroendocrine carcinoma.
Total number of patients 198
Age (median, range) 68, 28–92
Gender
Female 86
Male 112
Smoking-status
Never 74
Ex/Current 124
Histology
Adenocarcinoma 169
Squamous cell carcinoma 9
Other NSCLC 15
LCNEC 4
Clinical stage of NSCLC
IA 29
IB 14
IIA 2
IIB 6
IIIA 12
IIIB 30
IV 105
Chest CT
Normal 122
Emphysema 59
Fibrosis 17
EGFR mutation
Wild type 147
Ex18 G718S 1
Ex19 del 34
Ex21 L858R 15
EX19 del + Ex21 L858R 1
Ex 19del + T790M 1
patients with normal lung (n = 36, MST 874 days) and those
with emphysematous lungs (n = 6, MST 749 days) on chest
CT.
4. Discussion
We herein showed the frequency of EGFR mutation in
nonsmall cell lung cancer to be high in patients with the
following factors: female gender, no history of smoking,
adenocarcinoma, and normal lungs on chest CT. A survival
analysis of the patients with EGFR mutations, excluding
one patient with pulmonary ﬁbrosis, showed no diﬀerences
between smokers and never-smokers or between patients
with emphysema and those with normal lungs on chest
CT.
There is considerable variability in the susceptibility of
smokers to developing smoking-related pulmonary diseases
[14–16]. The incidence of lung canceris increased in patients
with emphysema and ﬁbrosis, and this eﬀect is independent
Table 2: Patient characteristics and EGFR mutation status.
Number EGFR mutation
(n,% ) P-value
Gender
Male 112 17, 15.2% P<0.0001
Female 86 35, 40.7%
Age
<65 80 23, 28.8% P = 0.5156
65≤ 118 29, 24.6%
Histology
Adenocarcinoma 169 50, 29.6% P = 0.0107
Nonadenocarcinoma 29 2, 6.9%
Smoking status
Never 74 29, 39.2% P = 0.0139
Ex/Current 124 23, 18.5%
Clinical stage of NSCLC
I-IIIA 63 21, 33.3% P = 0.1649
IIIB-IV 135 31, 22.9%
Chest CT
Normal 122 43, 35.2%
P = 0.0011 Emphysema 59 8, 13.6%
Fibrosis 17 1, 5.8%
of the eﬀect of cigarette smoking [17, 18]. We consider that
smokers with emphysema or ﬁbrosis are more susceptible
to smoking-related inﬂammation compared to those with
normal lungs. Although the frequency of EGFR mutation
was low in patients with emphysema and ﬁbrosis, the
frequency in those with normal lungs was not diﬀerent
between smokers and never-smokers. Our data suggested
that smokers with normal lungs were not susceptible
to smoking-related inﬂammation, and that nonsmall cell
lung cancer in smokers with normal lungs showed the
same biological features to that in never-smokers. Further
investigations are necessary to elucidate whether smoking-
related pulmonary diseases and lung cancer might result
fromoverlapping orassociatedgenetic variantsimplicated in
smoking-related inﬂammation.
Although a history of smoking and the coexistence of
emphysema were negatively associated with the frequency
of EGFR mutations, these clinical factors did not aﬀect
the prognosis of the patients with EGFR mutations treated
with geﬁtinib. Toyooka et al. showed that epidermal growth
factor receptor mutation, but not sex or smoking, is inde-
pendently associated with a favorable prognosis of geﬁtinib-
treated patients with lung adenocarcinoma [5]. EGFR-
TKI treatment should be considered in patients with an
EGFR mutation, even if they have a history of smoking or
emphysema without ﬁbrosis.
The presence of EGFR mutations in patients with
pulmonaryﬁbrosiswasrareinthisstudy.Onlyone(5.9%)of
17 patients with pulmonary ﬁbrosis had an EGFR mutation.
Preexisting chronic ILD is known as a risk factor for ILD
in geﬁtinib treatment [10]. In this study, one patient with4 Pulmonary Medicine
Table 3: Characteristics of patients with an EGFR mutation treated
with geﬁtinib.
Total number 43
Age (median, range) 67, 28–92
Gender
Male 13
Female 30
Smoking-status
Never 24
Ex/Current 19
Pack-years of smokers (median, range) 33, 2.5–225
Histology
Adenocarcinoma 42
Squamous cell carcinoma 1
Clinical stage of NSCLC
IB 2
IIIA 1
IIIB 7
IV 22
Recurrence 11
History of chemotherapy before geﬁtinib treatment
No 28
Yes 15
EGFR mutation
Ex18 G719C 1
Ex19 del 30
Ex21 L858R 10
Ex19 del + Ex21L858R 1
Ex19 del + Ex20 T790M 1
Chest CT
Normal 36
Emphysema 6
Fibrosis 1
pulmonary ﬁbrosis and an EGFR mutation treated with
geﬁtinib developed fatal ILD.
The present study had several limitations, including the
fact that it was observational and uncontrolled in design
and was performed at a single institution, with retrospective
collection of data. The results may have been subject to some
selection and treatment bias. The indications for therapy and
the selection of treatment were not uniform for all patients,
thereby limiting the evaluation of the eﬀects of treatment.
The data presented herein should not be interpreted as
providing an appropriate evaluation of the eﬃcacy of treat-
ment, which will require randomized prospective studies. A
multivariateanalysiscouldnotbeperformedduetothesmall
sample size, and it was therefore not possible to evaluate
the potential confounding eﬀects of various other variables
related to survival. However, the existence of emphysema
and ﬁbrosis on chest CT were prospectively identiﬁed at
the diagnosis of lung cancer. The EGFR mutation status
was identiﬁed before the EGFR-TKI treatment. Data on the
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Figure 1: (a) Overall survival of patients with an EGFR mutation
treated with geﬁtinib, according to smoking status (never smokers:
solid line; smokers: dotted line). +: censored patient. (b) Overall
survival of patients with an EGFR mutation treated with geﬁtinib,
according to underlying pulmonary disease (normal: solid line;
emphysema: dotted line). +: censored patient.
demographic characteristics and survival of patients were
unlikely to be aﬀected by the study design.
In summary, the frequency of EGFR mutations in
patients with normal lungs on chest CT was not diﬀerent
between smokers and never-smokers. Of patients with
sensitive EGFR mutations and normal lungs on chest CT,
smokers had a comparable prognosis with never-smokers.
Selecting patients on the basis of chest CT, rather than the
smoking status, would likely result in a population with a
greater sensitivity to geﬁtinib.
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